Antimony Resources Corp. has closed a flow-through financing, issuing over 10.6 million shares at $0.47 each, raising $5 million to fund exploration and development of its Bald Hill Antimony Project in New Brunswick, Canada. Bald Hill is noted as the highest-grade antimony deposit in North America, with drilling indicating significant mineralization open in all directions. The company aims to expand the project further based on new targets and recent land acquisitions. This financing supports Antimony Resources' goal to become a major North American antimony producer.
Antimony Resources Corp.'s recent $5 million flow-thru financing provides context for readers. For those following the Basic Materials sector, here is Pluang's market snapshot as of Oct 06, 2026 01:41 WIB: Among 38 priced US Basic Materials stocks, 29 rose and 9 fell. Dow Inc. traded at USD 28.48 with a 1-day gain of 1.82% and a typical hold time of 82 days, while Freeport-McMoRan Inc. was priced at USD 73.33, up 1.79%, with a shorter hold time of 69 days and a Pluang order activity skewed 58% Sell to 42% Buy. Ecolab Inc. stood out at USD 278.44, rising 1.73%, but with a high 91% Sell order activity and a longer hold time of 90 days.
BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...
Raymond James increased its price target for SBA Communications to $271 from $264, signaling a 68.6% upside from the current share price of $160.74. The growth is driven by rising mobile data demand, network expansions by wireless carriers, and stead...
NVIDIA stock reached a new all-time high, rising 28% year to date, driven by strong AI demand signals, including Foxconn's record revenue month attributed to AI product growth. Taiwan Semiconductor and Broadcom shares also rose, supporting the bullis...
Novavax shares surged 22% following Sanofi's rollout of the Nuvaxovid COVID-19 vaccine for the fall season, giving Novavax a commercial boost through its licensing deal. Unlike Moderna and BioNTech, Novavax earns royalties from Sanofi's sales rather ...
Hedera (HBAR) price has fallen about 23% from its late-September high near $0.131 to around $0.101, testing key support at $0.10. Daily charts show weaker momentum, but weekly indicators remain bullish, suggesting potential for recovery if $0.10 supp...
